United Kingdom (UK) : Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), a renowned global pharmaceutical company, has announced the introduction of Versavo (bevacizumab) in the United Kingdom (UK). Versavo, a biosimilar of Avastin1, is manufactured by Dr. Reddy’s and is approved for the treatment of various cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, and metastatic breast cancer2. This launch marks the debut of Dr. Reddy’s biosimilar product in the UK market, available in strengths of 100mg and 400mg single-use vials.
Versavo was initially introduced by Dr. Reddy’s in India in 2019, followed by launches in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same brand name. In Colombia, the product was launched under the brand name Persivia.
Dr. Jayanth Sridhar, Global Head of Biologics at Dr. Reddy’s, commented, “The launch of Versavo in a highly regulated market underscores our capability for global clinical development of high-quality biosimilar products. Versavo presents a promising treatment option for patients battling various types of cancers. This launch reaffirms our dedication to introducing more biosimilar and other essential biological products to address the unmet needs of patients, particularly in the field of oncology.”